Search Results - "Laroudie, Nicolas"

Clarification of vaccines: An overview of filter based technology trends and best practices by Besnard, Lise, Fabre, Virginie, Fettig, Michael, Gousseinov, Elina, Kawakami, Yasuhiro, Laroudie, Nicolas, Scanlan, Claire, Pattnaik, Priyabrata

“…Vaccines are derived from a variety of sources including tissue extracts, bacterial cells, virus particles, recombinant mammalian, yeast and insect cell…”
Get full text

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components by Fedosyuk, Sofiya, Merritt, Thomas, Peralta-Alvarez, Marco Polo, Morris, Susan J, Lam, Ada, Laroudie, Nicolas, Kangokar, Anilkumar, Wright, Daniel, Warimwe, George M, Angell-Manning, Phillip, Ritchie, Adam J, Gilbert, Sarah C, Xenopoulos, Alex, Boumlic, Anissa, Douglas, Alexander D

“…A variety of Good Manufacturing Practice (GMP) compliant processes have been reported for production of non-replicating adenovirus vectors, but important…”
Get full text

Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients by Le Guiner, Caroline, Montus, Marie, Servais, Laurent, Cherel, Yan, Francois, Virginie, Thibaud, Jean-Laurent, Wary, Claire, Matot, Béatrice, Larcher, Thibaut, Guigand, Lydie, Dutilleul, Maeva, Domenger, Claire, Allais, Marine, Beuvin, Maud, Moraux, Amélie, Le Duff, Johanne, Devaux, Marie, Jaulin, Nicolas, Guilbaud, Mickaël, Latournerie, Virginie, Veron, Philippe, Boutin, Sylvie, Leborgne, Christian, Desgue, Diana, Deschamps, Jack-Yves, Moullec, Sophie, Fromes, Yves, Vulin, Adeline, Smith, Richard H, Laroudie, Nicolas, Barnay-Toutain, Frédéric, Rivière, Christel, Bucher, Stéphanie, Le, Thanh-Hoa, Delaunay, Nicolas, Gasmi, Mehdi, Kotin, Robert M, Bonne, Gisèle, Adjali, Oumeya, Masurier, Carole, Hogrel, Jean-Yves, Carlier, Pierre, Moullier, Philippe, Voit, Thomas

“…Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by mutations in the dystrophin gene, without curative treatment yet available. Our…”
Get full text

Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application by Merten, Otto-Wilhelm, Charrier, Sabine, Laroudie, Nicolas, Fauchille, Sylvain, Dugué, Céline, Jenny, Christine, Audit, Muriel, Zanta-Boussif, Maria-Antonietta, Chautard, Hélène, Radrizzani, Marina, Vallanti, Giuliana, Naldini, Luigi, Noguiez-Hellin, Patricia, Galy, Anne

“…From the perspective of a pilot clinical gene therapy trial for Wiskott-Aldrich syndrome (WAS), we implemented a process to produce a lentiviral vector under…”
Get more information

Quantitative proteomic analysis of lentiviral vectors using 2-DE by Denard, Jérôme, Rundwasser, Stéphanie, Laroudie, Nicolas, Gonnet, Florence, Naldini, Luigi, Radrizzani, Marina, Galy, Anne, Merten, Otto-Wilhelm, Danos, Olivier, Svinartchouk, Fedor

“…Among the integrative gene therapy vectors developed to date, human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vectors (LV) are distinguished by…”
Get full text